Press Release

Cempra to use Curetis' Unyvero™ solution in its Phase III trial of its antibiotic solithromycin (CEM-101)

Curetis AG and Cempra, Inc. Collaborate on the Detection of Community-Acquired Bacterial Pneumonia Pathogens

Holzgerlingen, Germany, and Chapel Hill, N.C., USA 9 August, 2012

Curetis AG and Cempra Inc. (NASDAQ: CEMP) today announced a research and development collaboration to incorporate Curetis' Unyvero™ molecular diagnostic system into Cempra's upcoming global Phase 3 trial of the oral formulation of solithromycin in patients with community-acquired bacterial pneumonia (CABP).

Under the terms of the agreement, each party may use the generated data for its own product development and for its regulatory filings.

Cempra's randomized, double-blind Phase 3 trial comparing solithromycin against a comparator drug is expected to enroll over 800 patients in more than 100 clinical sites worldwide. Sputum samples from patients will be sent to Curetis for analysis with its Unyvero™ Solution and the CE-marked Unyvero™ P50 Pneumonia Application Cartridge. Molecular diagnostic data generated from the Unyvero™ Solution will be paired with clinical and traditional microbiology data to enhance the pathogen diagnosis rate in the trial. The trial is expected to start during the fourth quarter of 2012 and enrollment is expected to be completed in 2014.

"The collaboration with Cempra, which is developing much-needed novel antibiotics to overcome the resistance problem, is a perfect strategic fit for us," said Oliver Schacht, Ph.D., chief executive officer of Curetis AG. "The trial should provide us with an excellent opportunity to generate further data on the clinical sensitivity and specificity of our Unyvero solution in a commercially important indication, which is not yet included in the EU label, nor the one we are currently seeking in the U.S. Moreover, we hope to demonstrate the benefit of the Unyvero solution in an ambulant setting and also generate additional data from frozen samples."

David Oldach, M.D., senior vice president of clinical research of Cempra said, "Improving diagnostic accuracy for the detection of pathogens causing pneumonia is critical to improving the management of these patients. Curetis' Unyvero assay will enhance the trial's pathogen and resistance gene detection significantly, and positions our joint effort at the cutting edge of translational clinical science."

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
pr@curetis.com
www.curetis.com

Press Release

Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra added, “We believe that rapid and accurate identification of infectious pathogens will enable the better selection of appropriate antibiotic therapy and reduce the overuse of antibiotics.”

Curetis Disclaimer

CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use.The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero™ technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero™ product which may be sold at some future point in time in the U.S. have not yet been established.

About the Unyvero™ System

The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.

The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis can be performed with minimal operator time and without the need of skilled staff or special infrastructure. As a result, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.

The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyzes 39 DNA targets. Cartridges for further applications, for surgical site infections, blood stream infections and tuberculosis, are in preparation.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG are designed to enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The company is based in Holzgerlingen near Stuttgart, Germany. In 2011, Curetis signed a collaboration agreement with Sanofi Pasteur for the potential use of the Unyvero™ platform in a future global clinical trial.

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (7031) 49195-10
Fax +49 (7031) 49195-19
pr@curetis.com
www.curetis.com

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seekv to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: *This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business. The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.*

Contact

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany

Tel. +49 (7031) 49195-10
pr@curetis.com
www.curetis.com

Media Inquiries:

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners

info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Cempra, Inc.
Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.co m

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com